Menopause Relapse Prevention Strategies: A Complete Clinical Guide

Does Menopause Itself Relapse?

No. Menopause is defined by 12 months in a row without a period, and it does not reverse [1][3]. The years before it are perimenopause, which averages about four years and can run up to 10; pregnancy is still possible during that time [3].

What people usually mean by relapse is one of three things:

• Hot flashes and night sweats returning, or never fully settling.
• Vaginal and urinary symptoms that may worsen without treatment [3].
• Bone loss, which hormone therapy helps prevent [4].

The rest of this page deals with those three.

How Long Symptoms Can Last

The Study of Women's Health Across the Nation (SWAN) followed 3,302 women at seven US sites. The median total duration of frequent hot flashes and night sweats was 7.4 years, and among 881 women with a recorded final period, symptoms persisted a median of 4.5 years after it [2]. Women who first reported frequent symptoms while still premenopausal or early perimenopausal had the longest course, a median over 11.8 years with 9.4 years of persistence after the final period. Black women reported the longest total duration, a median of 10.1 years [2].

The Office on Women's Health gives a similar range: hot flashes and night sweats last 7 to 12 years on average, and longer for some women. The same page notes that without treatment, genital and urinary symptoms, including repeat urinary tract infections, may get worse over time [3].

Hormone Therapy: The Strongest Evidence for Symptom Control

The Menopause Society's 2022 position statement calls hormone therapy the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause, and notes that it prevents bone loss and fracture [4]. For women younger than 60 or within 10 years of menopause onset with no contraindications, the statement describes the benefit-risk ratio as favorable for bothersome hot flashes and for prevention of bone loss. For women starting more than 10 years after onset or after age 60, the ratio appears less favorable, with greater absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia. Risks vary by type, dose, duration, route, timing of initiation and whether a progestogen is used [4].

Practical points from the labels:

• The Premarin (conjugated estrogens) label says to use the lowest effective dose for the shortest duration consistent with treatment goals, starts treatment of vasomotor symptoms at 0.3 mg daily, and calls for periodic reassessment [9]. The Divigel label adds: consider initiating in women under 60 or less than 10 years since menopause onset [10].
• The Premarin label says a progestin should be considered for a postmenopausal woman with a uterus, to reduce the risk of endometrial cancer. It says a woman without a uterus does not need a progestin, although some hysterectomized women with a history of endometriosis may [9].
• The Premarin label lists these contraindications: undiagnosed abnormal genital bleeding, breast cancer or a history of it (outside selected palliative use), estrogen-dependent neoplasia, active or past DVT or PE, active or past stroke or heart attack, hepatic impairment or disease, protein C, protein S or antithrombin deficiency or other thrombophilia, and known anaphylaxis or angioedema with the product [9].

How long to continue is guided by periodic reassessment rather than a fixed clock. The 2022 statement says longer durations are acceptable for documented indications such as persistent hot flashes, with shared decision-making and regular review [4].

Risks to Weigh: Route, Regimen and Labels

Route and clot risk. In a UK nested case-control study (observational) of 80,396 women with venous thromboembolism and 391,494 matched controls aged 40 to 79, oral hormone therapy carried an adjusted odds ratio of 1.58 (95% CI 1.52 to 1.64), with 1.40 for estrogen-only and 1.73 for combined preparations. Transdermal preparations were not associated with venous thromboembolism risk [6].

Breast cancer risk differs by regimen. The WHI estrogen-alone trial included 10,739 women with a prior hysterectomy, and the estrogen-plus-progestin trial included 16,608 women with a uterus. In long-term follow-up, estrogen alone was associated with lower breast cancer incidence (HR 0.78, 95% CI 0.65 to 0.93) and lower breast cancer mortality (HR 0.60, 0.37 to 0.97) than placebo; estrogen plus progestin was associated with higher incidence (HR 1.28, 1.13 to 1.45), and its breast cancer mortality HR was 1.35 (0.94 to 1.95), which was not significant [11].

Progestogen choice may matter. In the French E3N cohort of 80,377 postmenopausal women with 2,354 invasive breast cancers, the relative risk was 1.00 (95% CI 0.83 to 1.22) for estrogen combined with progesterone, 1.16 (0.94 to 1.43) for estrogen with dydrogesterone, and 1.69 (1.50 to 1.91) for estrogen with other progestagens. The study found no evidence of a difference by route of estrogen [12].

Labels are in transition. In November 2025 the FDA asked application holders to remove cardiovascular disease, breast cancer and probable dementia statements from the boxed warnings and to keep the endometrial cancer box for systemic estrogen-alone products. For systemic products, the cardiovascular and breast cancer warnings stay in the Warnings and Precautions section [7]. On 12 February 2026 the FDA approved changes for a first batch of six products [8]. Not every label has changed: the Premarin label effective June 2026 and the Prempro label effective April 2026 still carry the older box [9][13], while the updated Divigel label has a box limited to endometrial cancer [10], and the current Prometrium and Estring labels have no boxed warning field in FDA label data [14][15].

Non-Hormonal Options for Hot Flashes

The Menopause Society's 2023 non-hormonal statement recommends, at Level I evidence, cognitive-behavioral therapy, clinical hypnosis, SSRIs/SNRIs, gabapentin and fezolinetant; oxybutynin at Levels I-II; and weight loss and stellate ganglion block at Levels II-III. It does not recommend paced respiration (Level I) or supplements and herbal remedies (Levels I-II) [5].

Three non-hormonal drugs are FDA-approved for menopausal hot flashes: Brisdelle (paroxetine mesylate 7.5 mg, approved 2013), Veozah (fezolinetant, 2023) and Lynkuet (elinzanetant, 2025) [16][17][18]. Gabapentin, other SSRIs/SNRIs and oxybutynin are used for hot flashes but are not FDA-labeled for it.

• Fezolinetant (Veozah) is an NK3 receptor antagonist, not a hormone, taken as 45 mg once daily. The label requires baseline liver tests and monthly testing for the first three months, then at months 6 and 9, and says not to start if ALT or AST is 2 times the upper limit of normal or more, or total bilirubin is 2 times that limit or more [17]. It carries a boxed warning for liver injury [17][19]. Per the label, in SKYLIGHT 1 the week-12 reduction in daily hot flash frequency with fezolinetant 45 mg versus placebo was 2.6 episodes (95% CI -3.4 to -1.7; 174 versus 175 women) [20].
• Elinzanetant (Lynkuet) blocks both NK1 and NK3 receptors and is taken as 120 mg, two 60 mg capsules, at bedtime. The label requires baseline liver tests and a follow-up at three months, and pregnancy must be excluded first [18]. Nervous-system effects such as drowsiness, fatigue, vertigo, dizziness and presyncope occurred in 11.9% versus 3.5% on placebo across the OASIS trials, and the drug is contraindicated in pregnancy, with contraception advised during treatment and for two weeks after [18]. In the 12-week OASIS 1 and 2 trials, elinzanetant reduced moderate-to-severe hot flashes by 3.22 and 3.24 more per day than placebo at week 12 [21].
• Paroxetine (Brisdelle) is taken as 7.5 mg at bedtime. It is a strong CYP2D6 inhibitor that lowers plasma levels of tamoxifen's active metabolite, and the label says to consider avoiding the combination [16].

The Menopause Society recommends SSRIs/SNRIs and gabapentin [5]. In a four-week trial of women with a history of breast cancer or reluctance to take hormones because of fear of breast cancer (191 with evaluable data), median hot flash scores fell 27% on placebo, 37% on venlafaxine 37.5 mg, and 61% on both 75 mg and 150 mg [22]. In a 12-week trial of 59 postmenopausal women, gabapentin 900 mg daily reduced hot flash frequency by 45% versus 29% on placebo [23].

Lifestyle: What Helps and What Does Not

Exercise is often suggested for hot flashes, but a UK randomized trial of 261 women having at least five hot flashes or night sweats a day found that neither of two exercise programs reduced their weekly frequency compared with controls (difference -8.9, 95% CI -20.0 to 2.2, and -5.2, -16.7 to 6.3) [24]. The Menopause Society recommends weight loss at Levels II-III for hot flashes, and cognitive-behavioral therapy and clinical hypnosis at Level I [5].

For general symptom management, MedlinePlus suggests dressing in layers, avoiding alcohol, spicy foods and caffeine, not smoking, maintaining a healthy weight, good sleep habits, and regular exercise, which it says can help sleep and mood [1].

What Hormone Therapy Does Not Prevent

Hormone therapy is not a prevention strategy for heart disease or dementia. A review by Women's Health Initiative investigators concluded that the trials do not support using hormone therapy to prevent cardiovascular disease, dementia or other chronic disease, while supporting it for moderate to severe symptoms and for initiation before age 60 in women without contraindications [25]. The Premarin label states that estrogen alone or with progestin should not be used to prevent cardiovascular disease or dementia [9].

• Mortality: across 27,347 women with 18 years of cumulative follow-up, all-cause mortality was HR 0.99 (95% CI 0.94 to 1.03) pooled, 1.02 with estrogen plus progestin and 0.94 (0.88 to 1.01) with estrogen alone [26].
• Dementia: the WHI Memory Study enrolled women aged 65 and older. Probable dementia occurred at HR 2.05 (1.21 to 3.48) with estrogen plus progestin and HR 1.49 (0.83 to 2.66, not significant) with estrogen alone [27][28]. The label notes that it is unknown whether the finding applies to younger postmenopausal women [9].
• Weight: an older Cochrane review of 22 randomized trials found no significant weight difference between hormone users and non-users (+0.66 kg with unopposed estrogen, 95% CI -0.62 to 1.93; -0.47 kg with combined therapy, -1.63 to 0.69) [29]. In the SWAN body-composition study, fat gain doubled at the start of the transition and lean mass declined, while weight itself climbed steadily without accelerating [30].

Genital and Urinary Symptoms

Without treatment, genital and urinary symptoms may worsen over time [3]. The Menopause Society puts the prevalence of the genitourinary syndrome of menopause at approximately 27% to 84% of postmenopausal women and notes that it is likely underdiagnosed and undertreated. Options include vaginal lubricants and moisturizers, vaginal estrogens, vaginal DHEA, systemic hormone therapy and oral ospemifene; long-term studies of endometrial safety for vaginal estrogen, vaginal DHEA and ospemifene are lacking [31]. For bothersome symptoms not relieved by over-the-counter products, the 2022 statement recommends low-dose vaginal estrogen, vaginal DHEA (prasterone) or oral ospemifene [4]. Ospemifene and vaginal prasterone are FDA-approved for painful intercourse due to menopause [32][33].

Monitoring While on Treatment

The Menopause Society calls for periodic reevaluation of the benefits and risks of continuing therapy [4], and the estrogen labels say postmenopausal women should be re-evaluated periodically to determine whether treatment is still necessary [9].

Specific checks that come with specific drugs:

• Fezolinetant: liver tests at baseline, monthly for three months, then at months 6 and 9 [17].
• Elinzanetant: liver tests at baseline and at three months, with pregnancy excluded before starting [18].
• Estrogen: the Premarin label warns about gallbladder disease, advises discontinuing if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs, and advises monitoring thyroid function in women on thyroid replacement therapy [9][10].

The FDA says it has no evidence that compounded bioidentical hormones are safe and effective and recommends FDA-approved hormone therapy [34], and ACOG advises that compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist [35].